Nasdaq Initial Listing Path Outlined on RMTG Investor Call

Shareholder questions at small companies tend to circle one topic: when does the stock move to a national exchange? Regenerative Medical Technology Group Inc. (RMTG) took the question directly on an investor video call held August 20, 2026. It filed the transcript with the SEC on August 25 under Item 8.01, giving a public record of how management describes the Nasdaq initial listing process and what it will not promise.

A checklist, and work to do before it

Asked what the path to Nasdaq looks like, the executive speaking for the company, identified only as Dave in the transcript, described a published checklist. He said Nasdaq is clear about its financial thresholds and named the categories: a net income test, stockholders’ equity, market value, a minimum price and public float. He said he had helped lead a company’s IPO in 2018.

The company’s own task, he said, is to align the business and balance sheet with those standards and tiers, then file an application for Nasdaq review. He added a caution: “we can’t guarantee timing of the outcome of an uplisting.” The company’s desire to get there, he said, is the extent of what it can state.

Naming the Nasdaq listing requirements is the easy part of an uplisting plan. The harder part is showing which of them the company meets today, and the call did not.

Growth that comes with debt

A second question raised the company’s liabilities and rising interest expense. The executive agreed with the premise. He said first-quarter 2026 revenue rose 90% from a year earlier and second-quarter revenue roughly quadrupled. He put revenue for all of 2025 at $5.1 million and indicated that first-half 2026 revenue exceeds that figure.

Growth has been funded with debt, he said, including the purchase of Global Stem Cell Group, a new laboratory and a relationship to produce biologics in Argentina. He pointed to derivative and fair value charges as part of the cost. The plan to close the gap, in his words, is to scale higher-margin, recurring products and training revenue over several quarters.

The share structure and the business model

The executive said authorized shares were cut from 6.5 billion, a figure inherited from the predecessor entity, to 100 million. The call did not tie the reduction to a listing application.

Management described a physician training and certification business as the entry point to product sales. He said more than 478 doctors signed up for last year’s global annual event, that the company held 15 events last year and plans more than 12 this year. The doctors, he said, then have the opportunity to buy regenerative products, with the company as their first source.

How to read a call transcript

The revenue growth rates and dollar figures in the transcript are statements by management on a video call, filed as an exhibit. They are not audited results, and the filing includes no financial statements. A Nasdaq application would be measured against reported figures, so the gap between what executives say and what the company has filed is the useful comparison. The executive also described a data partnership giving the company access to 30 years of about 60 million records.

What to watch

The transcript contains no application date, no announced venue and no statement of which Nasdaq tier the company would pursue. For readers following RMTG, the facts to monitor are the ones the executive named himself: reported stockholders’ equity, the share price and the public float, along with the interest and derivative charges that weigh on the income statement. Any formal step toward a Nasdaq filing would appear in a later press release or SEC filing.